Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001104659-24-090990 0001697316 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 05/22/2025 false 0001652935 005083100 Actuate Therapeutics, Inc. 1751 River Run Suite 400 Fort Worth TX 76107 Bios Equity Partners, LP (817) 984-9197 1751 River Run, Suite 400 Fort Worth TX 76107 Rick Jordan; Polsinelli PC (214) 397-0030 2950 N. Harwood St., Suite 2100 Dallas TX 75201 0001697316 N BIOS FUND I, LP b WC N DE 0.00 525797.00 0.00 525797.00 525797.00 N 2.7 PN Shared voting and dispositive power consists of shares of common stock, par value $0.000001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001700297 N BIOS FUND I QP, LP b WC N DE 0.00 307538.00 0.00 307538.00 307538.00 N 1.6 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001714576 N BIOS FUND II, LP b WC N DE 0.00 308211.00 0.00 308211.00 308211.00 N 1.6 PN Shared voting and dispositive power consists of (i) 300,143 Shares, and (ii) 8,068 Shares issuable upon the exercise of warrants, directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 19,627,728 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 8,068 Shares issuable upon the exercise of warrants held by Bios Fund II. 0001716869 N BIOS FUND II QP, LP b WC N DE 0.00 1006788.00 0.00 1006788.00 1006788.00 N 5.1 PN Shared voting and dispositive power consists of (i) 980,433 Shares, and (ii) 26,355 Shares issuable upon the exercise of warrants, directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 19,646,015 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 26,355 Shares issuable upon the exercise of warrants held by Bios Fund II QP. 0001728851 N BIOS FUND II NT, LP b WC N DE 0.00 134776.00 0.00 134776.00 134776.00 N 0.7 PN Shared voting and dispositive power consists of (i) 131,248 Shares, and (ii) 3,528 Shares issuable upon the exercise of warrants, directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 19,623,188 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 3,528 Shares issuable upon the exercise of warrants held by Bios Fund II NT. 0001791917 N BIOS FUND III, LP b WC N DE 0.00 383791.00 0.00 383791.00 383791.00 N 2.0 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund III, LP ("Bios Fund III"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001791916 N BIOS FUND III QP, LP b WC N DE 0.00 2506667.00 0.00 2506667.00 2506667.00 N 12.8 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund III QP, LP ("Bios Fund III QP"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001791910 N BIOS FUND III NT, LP b WC N DE 0.00 404814.00 0.00 404814.00 404814.00 N 2.1 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund III NT, LP ("Bios Fund III NT"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001813311 N BP DIRECTORS, LP b OO N DE 0.00 116801.00 0.00 116801.00 116801.00 N 0.6 PN Shared voting and dispositive power consists of (i) 84,971 Shares, and (ii) 31,884 Shares issuable upon the exercise of stock options, directly held by BP Directors, LP ("BP Directors"). Percentage based on 19,651,544 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 31,884 Shares issuable upon the exercise of stock options held by BP Directors. 0001771378 N BIOS ACTUATE CO-INVEST I, LP b WC N DE 0.00 300749.00 0.00 300749.00 300749.00 N 1.5 PN Shared voting and dispositive power consists of Shares directly held by Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001825398 N BIOS ACTUATE CO-INVEST II, LP b WC N DE 0.00 2094650.00 0.00 2094650.00 2094650.00 N 10.7 PN Shared voting and dispositive power consists of Shares directly held by Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001956704 N BIOS ACTUATE CO-INVEST III, LP b WC N DE 0.00 573394.00 0.00 573394.00 573394.00 N 2.9 PN Shared voting and dispositive power consists of Shares directly held by Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001988639 N BIOS CLINICAL OPPORTUNITY FUND, LP b WC N DE 0.00 1259427.00 0.00 1259427.00 1259427.00 Y 6.4 PN Shared voting and dispositive power consists of Shares directly held by Bios Clinical Opportunity Fund, LP ("Bios Clinical Opportunity Fund"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0002028708 N BIOS 2024 CO-INVEST, LP b WC N DE 0.00 125000.00 0.00 125000.00 125000.00 Y 0.6 PN Shared voting and dispositive power consists of Shares directly held by Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). Percentage based on 19,619,660 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001813314 N BIOS EQUITY PARTNERS, LP b AF N TX 0.00 950136.00 0.00 950136.00 950136.00 N 4.8 PN Shared voting and dispositive power consists (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP and (iii) 84,917 Shares directly held by BP Directors, in each case (i-iii), as of the date hereof, and (iv) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 19,651,544 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 31,884 Shares issuable upon the exercise of stock options held by BP Directors. 0001813313 N BIOS EQUITY PARTNERS II, LP b AF N TX 0.00 1750524.00 0.00 1750524.00 1750524.00 N 8.9 PN Shared voting and dispositive power consists of (i) 300,143 Shares directly held by Bios Fund II, (ii) 980,433 Shares directly held by Bios Fund II QP, (iii) 131,248 Shares directly held by Bios Fund II NT, (iv) 300,749 Shares directly held by Bios Actuate Co-Invest I, in each case (i-iv), as of the date hereof, (v) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (vi) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (vii) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (v-vii), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 19,657,611 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT. 0001831976 N BIOS EQUITY PARTNERS III, LP b AF N TX 0.00 5963316.00 0.00 5963316.00 5963316.00 N 30.4 PN Shared voting and dispositive power consists of (i) 383,791 outstanding Shares directly held by Bios Fund III, (ii) 2,506,667 outstanding Shares directly held by Bios Fund III QP, (iii) 404,814 outstanding Shares directly held by Bios Fund III NT, (iv) 2,094,650 outstanding Shares directly held by held by Bios Actuate Co-Invest II and (v) 573,394 outstanding Shares directly held by held by Bios Actuate Co-Invest III, in each case, as of the date hereof. Bios Equity Partners III, LP ("Bios Equity III") is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. In its capacity as the general partner of these entities, Bios Equity III may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 19,619,660 Shares outstanding as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0002000747 N BIOS EQUITY COF, LP b AF N TX 0.00 1384427.00 0.00 1384427.00 1384427.00 Y 7.1 PN Shared voting and dispositive power consists of (i) 1,259,427 Shares directly held by Bios Clinical Opportunity Fund and (ii) 125,000 Shares directly held by Bios 2024 Co-Invest, in each case, as of the date hereof. Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund and Bios 2024 Co-Invest. In its capacity as the general partner of these entities, Bios Equity COF may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 19,619,660 Shares outstanding as reported in the Form 10-Q filed by the Issuer on May 15, 2025. 0001813270 N CAVU MANAGEMENT, LP b AF N TX 0.00 8663976.00 0.00 8663976.00 8663976.00 N 44.0 PN Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, in each case (i-xii), as of the date hereof, (xiii) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xiv) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xv) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xvi) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xiii-xvi), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III (collectively, the "Bios Equity Entities"). Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. 0001813845 N BIOS CAPITAL MANAGEMENT, LP b AF N TX 0.00 10048403.00 0.00 10048403.00 10048403.00 Y 51.0 PN Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, (xiii) 1,259,427 Shares directly held by Bios Clinical Opportunity Fund, (xiv) 125,000 Shares directly held by Bios 2024 Co-Invest, in each case (i-xiv), as of the date hereof, (xv) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xvi) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xvii) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xviii) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xv-xviii), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Bios Equity COF is the general partner of Bios Clinical Opportunity Fund and Bios 2024 Co-Invest. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I, Bios Equity II, Bios Equity III and Bios Equity COF. In its capacity as a general partner of Bios Equity I, Bios Equity II, Bios Equity III and Bios Equity COF Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. 0001813310 N CAVU ADVISORS, LLC b AF N TX 0.00 8663976.00 0.00 8663976.00 8663976.00 N 44.0 PN Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, in each case (i-xii), as of the date hereof, (xiii) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xiv) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xv) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xvi) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xiii-xvi), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Cavu Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. 0001813844 N BIOS ADVISORS GP, LLC b AF N TX 0.00 10048403.00 0.00 10048403.00 10048403.00 Y 52.4 PN Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, (xiii) 1,259,427 Shares directly held by Bios Clinical Opportunity Fund, (xiv) 125,000 Shares directly held by Bios 2024 Co-Invest, in each case (i-xiv), as of the date hereof, (xv) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xvi) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xvii) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xviii) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xv-xviii), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Bios Equity COF is the general partner of Bios Clinical Opportunity Fund and Bios 2024 Co-Invest. Bios Management is a general partner of Bios Equity I, Bios Equity II, Bios Equity III and Bios Equity COF. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. 0001813316 N LESLIE W. KREIS b AF OO N X1 69375.00 8663976.00 69375.00 8663976.00 8733351.00 N 44.4 IN Sole voting and dispositive power consists of Shares directly held by Circle K, Invesco, LP ("Circle K"), over which Mr. Kreis has sole voting and investment control. Circle K is wholly owned by Mr. Kreis. Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, in each case (i-xii), as of the date hereof, (xiii) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xiv) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xv) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xvi) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xiii-xvi), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Cavu Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. 0001789490 N AARON G.L. FLETCHER b AF OO N X1 60973.00 10048403.00 60973.00 10048403.00 10109376.00 Y 51.3 PN Excludes (i) 8,056 Shares directly held by KF Legacy Trust U/A/D December 7, 2016, which has an independent trustee, and (ii) 8,056 Shares directly held by KF Legacy Trust U/A/D December 7, 2016, which has an independent trustee. Dr. Fletcher disclaims beneficial ownership of the shares held by each of the KF Legacy Trust U/A/D December 7, 2016 and the MF Legacy Trust U/A/D December 7, 2016, which are trusts for the benefit of his children, other than to the extent he may have a pecuniary interest therein. Sole voting and dispositive power consists of 60,973 Shares directly held by Dr. Fletcher. Shared voting and dispositive power consists of (i) 525,797 Shares directly held by Bios Fund I, (ii) 307,538 Shares directly held by Bios Fund I QP, (iii) 84,917 Shares directly held by BP Directors (iv) 300,143 Shares directly held by Bios Fund II, (v) 980,433 Shares directly held by Bios Fund II QP, (vi) 131,248 Shares directly held by Bios Fund II NT, (vii) 300,749 Shares directly held by Bios Actuate Co-Invest I, (viii) 383,791 Shares directly held by Bios Fund III, (ix) 2,506,667 Shares directly held by Bios Fund III QP, (x) 404,814 Shares directly held by Bios Fund III NT, (xi) 2,094,650 Shares directly held by Bios Actuate Co-Invest II, (xii) 573,394 Shares directly held by Bios Actuate Co-Invest III, (xiii) 1,259,427 Shares directly held by Bios Clinical Opportunity Fund, (xiv) 125,000 Shares directly held by Bios 2024 Co-Invest, in each case (i-xiv), as of the date hereof, (xv) 31,884 Shares issuable upon exercise of stock options, directly held by BP Directors, (xvi) 8,068 Shares issuable upon exercise of warrants directly held by Bios Fund II, (xvii) 26,355 Shares issuable upon exercise of warrants directly held by Bios Fund II QP and (xviii) 3,528 Shares issuable upon exercise of warrants directly held by Bios Fund II NT, in each case (xv-xviii), which are exercisable or will be immediately exercisable within 60 days of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Actuate Co-Invest I. Bios Equity III is the general partner of Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II and Bios Actuate Co-Invest III. Bios Equity COF is the general partner of Bios Clinical Opportunity Fund and Bios 2024 Co-Invest. Bios Management is a general partner of Bios Equity I, Bios Equity II, Bios Equity III and Bios Equity COF. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 19,689,495 outstanding Shares, including (i) 19,619,660 Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025 plus (ii) 37,951 Shares issuable upon the exercise of warrants collectively by Bios Fund II, Bios Fund II QP, and Bios Fund II NT plus (iii) 31,884 Shares issuable upon exercise of stock options held by BP Directors. Common Stock, par value $0.0001 per share Actuate Therapeutics, Inc. 1751 River Run Suite 400 Fort Worth TX 76107 On May 22, 2025, options to acquire 15,000 Shares were granted to Dr. Fletcher in connection with his service as a director of the Issuer. Such stock options have an exercise price of $10.10, will fully vest on May 22, 2026, and will expire on May 21, 2036. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. Except as otherwise disclosed in Item 3 above, none of the Reporting Persons, nor, to the best of the Reporting Persons' knowledge, any of their respective executive officers or directors, as applicable, has acquired or disposed of, any securities of the Issuer during the 60 days prior to the date hereof. Exhibit 99.1: Joint Filing Agreement (incorporated by reference to Exhibit 6 of the original Schedule 13D, filed August 19, 2024) Exhibit 99.2: Power of Attorney BIOS FUND I, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND I QP, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND II, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND II QP, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND II NT, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND III, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND III QP, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS FUND III NT, LP John Fucci Attorney-in-Fact 05/27/2025 BP DIRECTORS, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS ACTUATE CO-INVEST I, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS ACTUATE CO-INVEST II, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS ACTUATE CO-INVEST III, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS CLINICAL OPPORTUNITY FUND, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS 2024 CO-INVEST, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS EQUITY PARTNERS, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS EQUITY PARTNERS II, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS EQUITY PARTNERS III, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS EQUITY COF, LP John Fucci Attorney-in-Fact 05/27/2025 CAVU MANAGEMENT, LP John Fucci Attorney-in-Fact 05/27/2025 BIOS CAPITAL MANAGEMENT, LP John Fucci Attorney-in-Fact 05/27/2025 CAVU ADVISORS, LLC John Fucci Attorney-in-Fact 05/27/2025 BIOS ADVISORS GP, LLC John Fucci Attorney-in-Fact 05/27/2025 LESLIE W. KREIS John Fucci Attorney-in-Fact 05/27/2025 AARON G.L. FLETCHER John Fucci Attorney-in-Fact 05/27/2025